CBIZ Investment Advisory Services LLC Invests $58,000 in Repligen Co. (NASDAQ:RGEN)

CBIZ Investment Advisory Services LLC acquired a new position in Repligen Co. (NASDAQ:RGEN) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 400 shares of the biotechnology company’s stock, valued at approximately $58,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Champlain Investment Partners LLC boosted its holdings in shares of Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Repligen in the fourth quarter worth approximately $52,492,000. Allspring Global Investments Holdings LLC grew its position in Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after acquiring an additional 203,011 shares during the last quarter. DF Dent & Co. Inc. raised its stake in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in shares of Repligen by 421.9% in the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after acquiring an additional 102,100 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of RGEN stock opened at $150.62 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a market cap of $8.44 billion, a P/E ratio of -295.33, a P/E/G ratio of 4.54 and a beta of 0.95. The business’s 50 day moving average price is $157.19 and its 200-day moving average price is $148.50. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $200.23.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. On average, equities research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on RGEN shares. HC Wainwright reaffirmed a “buy” rating and set a $180.00 target price on shares of Repligen in a report on Friday, February 21st. Canaccord Genuity Group raised their price objective on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Finally, Royal Bank of Canada lifted their price target on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.